MaxCyte is the leader in providing clinical/commercial cell modification technologies and unparalleled expertise to the global leaders in life sciences. MaxCyte’s revolutionary transfection technology platform enables the discovery, development, manufacturing and delivery of innovative and important therapeutic products for a wide range of diseases.

MaxCyte provides critical enablement for cell therapeutics targeting a broad range of chronic diseases by allowing the controlled modification of cell function. By providing unparalleled consistency, scalability, and loading efficiency while avoiding the inherent drawbacks to alternative methods, MaxCyte enables the development of therapies not otherwise commercializable. MaxCyte’s clinical-grade cell loading technologies are fully developed and well validated, with an FDA Master File in place, NIH RAC cleared, two Ph IIa trials on-going, two additional Phase II programs licensed and additional programs headed for clinical trials and commercialization. Medinet., LTD of Japan, has commercially launched its therapeutic service enabled by MaxCyte’s technology for oncology patients in 2008.

Drawing upon its cell therapy expertise, MaxCyte has launched the MaxCyte STX Scalable Transfection System expressly for rapid, scalable and reagent-free transfection for small molecule drug discovery using cell based assays for high throughput and high content screening, preclinical protein production, and other cell based applications.